Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 2/20 | 0.50 |
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.42 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.42 |
| ▸ | KCNQ3 known ✓ | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 known ✓ | O43526 | 1/20 | 0.41 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | TPH1 | P17752 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | CCR6 | P51684 | 1/20 | 0.44 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2108091 | 1.00 | PPARG (0.50) | PPARGEPHX2TPH1MAPTMEN1 | |
| SCHEMBL838697 | 0.98 | PPARG (0.51) | PPARGEPHX2TPH1MAPTMEN1 | |
| SCHEMBL839736 | 0.98 | PPARG (0.51) | PPARGEPHX2TPH1MAPTMEN1 | |
| SCHEMBL1064642 | 0.98 | PPARG (0.51) | PPARGEPHX2TPH1MAPTMEN1 | |
| Hydrochloric Acid SCHEMBL7224972 | 0.95 | DPP4 (0.48) | PPARGEPHX2TPH1MAPTMEN1 | |
| SCHEMBL7224977 | 0.94 | DPP4 (0.49) | PPARGEPHX2TPH1MAPTMEN1 | |
| SCHEMBL7960935 | 0.90 | SLC7A5 (0.48) | PPARGEPHX2TPH1ALDH1A1SLC7A5 | |
| L-Tyrosine Ethylester SCHEMBL9331146 | 0.85 | SLC7A5 (0.59) | TPH1SLC7A5 | |
| Hydrochloric Acid SCHEMBL7152109 | 0.85 | LMNA (0.50) | PPARGTPH1MAPTMEN1LMNA | |
| L-Tyrosine Ethylester SCHEMBL595118 | 0.85 | SLC7A5 (0.59) | TPH1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347615-B1 | PROCESS FOR MAKING MELFLUFEN OR A SALT THEREOF | SYNTHON BV (NL) | 2025-05-21 | — | — | EP | disclosed |
| CN-116348109-B | Piperazine derivative, and preparation method and application thereof | 浙江海正药业股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20240358838-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | ONCOPEPTIDES AB (SE) | 2024-10-31 | — | — | US | disclosed |
| US-20240270680-A1 | PROCESS FOR MAKING MELFLUFEN OR A SALT THEREOF | SYNTHON B.V. (NL) | 2024-08-15 | — | — | US | disclosed |
| EP-4347615-A1 | PROCESS FOR MAKING MELFLUFEN OR A SALT THEREOF | Synthon B.V. (NL) | 2024-04-10 | — | — | EP | disclosed |
| EP-3015488-B1 | PRODUCTION METHOD FOR POLYAMINO ACID | TAKEDA PHARMACEUTICALS CO (JP) | 2024-03-06 | — | — | EP | disclosed |
| US-11896668-B2 | Lyophilized preparation of cytotoxic dipeptides | ONCOPEPTIDES AB (SE) | 2024-02-13 | — | — | US | disclosed |
| CN-116348109-A | Piperazine derivative, and preparation method and application thereof | 浙江海正药业股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-4122482-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | Oncopeptides AB (SE) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022253894-A1 | PROCESS FOR MAKING MELFLUFEN OR A SALT THEREOF | SYNTHON B.V. (NL) | 2022-12-08 | — | — | WO | disclosed |
| CN-1155612-C | Endothelin antagon | 中国人民解放军军事医学科学院毒物药 | 2004-06-30 | — | — | CN | disclosed |
| CN-1155611-C | Endothelin antagon | 中国人民解放军军事医学科学院毒物药 | 2004-06-30 | — | — | CN | disclosed |
| US-20040097421-A1 | Melphalan derivatives and their use as cancer chemotherapeutic drugs | ONCOPEPTIDES INNOVATION AB (SE) | 2004-05-20 | — | — | US | disclosed |
| US-20040038906-A1 | Tripeptides; acidification; saponification | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES, P.L.A. (CN) | 2004-02-26 | — | — | US | disclosed |
| US-20030162721-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PEPTICHEMIO | PTC PHARMA AG (CH) | 2003-08-28 | — | — | US | disclosed |
| EP-1290011-A1 | MELPHALAN DERIVATIVES AND THEIR USE AS CANCER CHEMOTHERAPEUTIC DRUGS | Oncopeptides AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| CN-1330076-A | Endothelin antagon | INST OF TOXIC MEDICINES PLA S (CN) | 2002-01-09 | — | — | CN | disclosed |
| CN-1330077-A | Endothelin antegon | INST OF TOXIC MEDICINES PLA S (CN) | 2002-01-09 | — | — | CN | disclosed |
| CN-1330075-A | Endothelin antagon | INST OF TOXIC MEDICINES PLA S (CN) | 2002-01-09 | — | — | CN | disclosed |
| WO-2001096367-A1 | MELPHALAN DERIVATIVES AND THEIR USE AS CANCER CHEMOTHERAPEUTIC DRUGS | ONCOPEPTIDES AB (SE) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11896668-B2 | Lyophilized preparation of cytotoxic dipeptides | TREH, SORD, SI | PPARG 4006/4885DPP4 30/4885OPRM1 2040/4885 |
| US-20240270680-A1 | PROCESS FOR MAKING MELFLUFEN OR A SALT THEREOF | CYP2F1, CYP4F3, CYP4F2 | PPARG 3983/4885DPP4 1532/4885OPRM1 1624/4885 |
| US-20040097421-A1 | Melphalan derivatives and their use as cancer chemotherapeutic drugs | MCL1, LNPEP, MYADM | PPARG 4666/4885DPP4 242/4885OPRM1 3504/4885 |
| US-20240358838-A1 | LYOPHILIZED PREPARATION OF CYTOTOXIC DIPEPTIDES | TREH, TYMP, SI | PPARG 4302/4885DPP4 754/4885OPRM1 1027/4885 |
| US-20040038906-A1 | Tripeptides; acidification; saponification | VIP, DNPEP, ECE1 | PPARG 4051/4885DPP4 13/4885OPRM1 4752/4885 |
| US-20030162721-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PEPTICHEMIO | VIP, HBB, PTMS | PPARG 4061/4885DPP4 1967/4885OPRM1 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.